Company / Capital Expenditures
Alaunos Therapeutics, Inc. Capital Expenditures History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
-
FY2025
5-year range
$0 / $9.8M
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $216,000 to $0 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Alaunos Therapeutics, Inc.'s capital expenditures has declined for 4 consecutive years.
- In FY2025, capital expenditures decreased 100.0% year-over-year.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0 | -100.0% |
| FY2024 | $197.0K | -8.8% |
| FY2023 | $216.0K | -93.5% |
| FY2022 | $3.3M | -66.0% |
| FY2021 | $9.8M | +2030.3% |
| FY2020 | $459.0K | -37.7% |
| FY2019 | $737.0K | +33.8% |
| FY2018 | $551.0K | -52.3% |
| FY2013 | $1.2M | +521.5% |
| FY2012 | $186.0K | +1590.9% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026